Company Description: Ilios Therapeutics is a biopharmaceutical company discovering and developing rationally-designed multi-targeted therapeutics to combat neurodegenerative diseases. Our innovative chemistry platform merges naturally-occurring bioactive pharmacophores with glutathione and fatty acids to create first-in-class small molecules that synergistically modulate three complementary upstream mechanisms involved in neurodegeneration: oxidative stress, brain inflammation and protein misfolding. Our modular platform enables the synthesis of proprietary new treatments for ALS, AD and PD. Our team operates at the Pagliuca Harvard Life Lab in Cambridge, MA, and includes expertise in neuroscience drug discovery, medicinal chemistry and translational biology. Lead candidates for ALS-FTD are expected by 2024.